目的：评价玻璃体腔注射雷珠单抗联合Ahmed引流阀植入术相对于单纯Ahmed引流阀植入术治疗新生血管性青光眼(NVG)的有效性和安全性。

方法：计算机检索PubMed、EMbase、Cochrane Library、美国科学引文索引数据库(SCI)、中国知网(CNKI)、中文科技期刊数据库(VIP)、万方数据库、中国生物医学文献服务系统(CBM)等多个数据库，查找自建库至2020-03-20关于雷珠单抗与Ahmed引流阀植入术治疗NVG的文献，同时查阅相关参考文献。对纳入研究行质量评价和资料提取，运用RevMan 5.3和STATA 12.0软件行Meta分析。

结果：纳入7篇临床研究，346例349眼NVG患者，质量评价均为中高质量，各项研究基本特征同质性较好。Meta分析结果显示，与单纯 Ahmed引流阀植入组相比，雷珠单抗联合Ahmed引流阀植入组患者在术后1wk，1mo时眼压更低，但术后6mo时无差异； 雷珠单抗联合Ahmed引流阀植入组患者在术后1、3mo时最佳矫正视力更好，但术后6mo时无差异。两组患者术后前房出血率及抗青光眼药物使用数量无差异。

结论：与单纯Ahmed引流阀植入术相比，雷珠单抗联合Ahmed引流阀植入术治疗NVG，患者术后早期眼压及最佳矫正视力疗效更好，但术后前房出血率和抗青光眼药物的使用数量无明显变化。

METHODS: Computers were used to search PubMed, EMbase, Cochrane Library, American Scientific Citation Index Database(SCI), China Knowledge Network(CNKI), Chinese Science and Technology Journal Database(VIP), Wanfang Database, China Biomedical Document Service System(CBM), and to find literature about ranibizumab and Ahmed drainage valve implantation in the treatment of NVG. At the same time, relevant references were consulted. The search time limit was establishment until March 20, 2020. Quality evaluation and data extraction on the included studies were performed. RevMan 5.3 and STATA 12.0 software were used for Meta-analysis.

RESULTS: The included 7 clinical studies included 346 patients(349 eyes), and the quality was evaluated as medium to high quality. The homogeneity of the basic characteristics of various studies was better. Compared with the pure Ahmed drainage valve implantation group(the control group), the ranibizumab combined with Ahmed drainage valve implantation group(the experimental group)had lower intraocular pressure at 1wk and 1mo after surgery. There was no statistical difference at 6mo after surgery. The BCVA of the experimental group was better than that of the control group at 1mo and 3mo, and there was no significant difference at 6mo after surgery. There was no significant difference in the rate of anterior chamber bleeding and the number of anti-glaucoma drugs used between the two groups.

CONCLUSION: Compared with pure Ahmed drainage valve implantation, ranibizumab combined with Ahmed drainage valve implantation has better postoperative intraocular pressure and best corrected visual acuity in the early stage in the treatment of NVG, and the difference in the late postoperative period is not significant. It cannot reduce the rate of postoperative anterior chamber bleeding, and cannot reduce the use of anti-glaucoma drugs. This conclusion needs to be further confirmed by more high-quality clinical randomized controlled studies.